A study to create control arms using current and future information in patients with lung cancer.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. \> 18 years of age at the time of informed consent
2. Pathologically confirmed locally advanced or metastatic NSCLC
3. ECOG Performance of less than or equal to 1 within 4 weeks prior to starting index therapy.
4. Life expectancy of more than 3 months
5. Able to understand and sign informed consent
6. Evidence of measurable disease (as assessed by the Investigator) on available imaging (e.g CT, MRI, PET)
\*see protocol for cohort specific inclusion criteria\*
Exclusion Criteria:
1. Actively on a clinical trial of an investigational agent
2. Currently receiving active systemic therapy for another malignancy
3. Eligible for treatment with curative intent
\*see protocol for cohort specific exclusion criteria\*
Primary outcome measure(s)
Assess Objective Response Rate (ORR) by cohort in patients with metastatic NSCLC treated in second or third line with NCCN recommended therapies — September 2025-April 2029
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.